Recent News

• 05.28.2026 - Allogene Therapeutics Announces Planned CEO Succession
• 05.26.2026 - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
• 05.13.2026 - Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
• 05.06.2026 - Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
• 04.21.2026 - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Recent Filings

• 05.28.2026 - 8-K Current report
• 05.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.21.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 8-K Current report